Orexo has long experience in successful collaborations, which has enabled the development and launch of novel products, offering improved treatment options for patients worldwide.
We continuously evaluate new potential partnerships to grow our business and meet our goals. In-licensing of products, technologies or development projects which can complement our commercial strategy and out-licensing of our innovative project assets is of highest priority.
For questions regarding business development please contact:
US
Robert Coburn
- Tel: +1 (0)855 982 7658
- Email: Robert.coburn@orexo.com
Other countries
Petter Wereén, VP Procurement and Business Development
- Tel +46 18 780 88 00
- Email: Petter.Wereen@orexo.com
Orexos partners:
Providing commercialization of ZUBSOLV® in the EU
Providning commercialization of Abstral® outside the US and EU, where patents have expired
Providing commercialization of Edluar® worldwide ex the US
Development of OX-MPI
Development of MODIA®, vorvida® and deprexis®